Clinical trial · Observational
3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis
Assessment of 3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis in Cancer Patients
NCT03546803CI-TRIAL-00040076completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study observes a liquid skin protectant that is a polymeric-cyanoacrylate solution designed to protect intact or damaged skin due to radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiation Dermatitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3M™ Cavilon™ Advanced Skin Protectant | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cohort A
- description
- Head and Neck Patients; Photon or Proton Treatment with product
- interventionNames
- Other: 3M™ Cavilon™ Advanced Skin Protectant
- label
- Cohort B
- description
- Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
- interventionNames
- Other: 3M™ Cavilon™ Advanced Skin Protectant
- label
- Cohort C
- description
- Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
- interventionNames
- Other: 3M™ Cavilon™ Advanced Skin Protectant
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18years. * Patient has initial or recurrent disease * Undergoing external beam radiotherapy at the Mayo Clinic Rochester campus Note: Patients who are undergoing concurrent chemotherapy are eligible * Ability to complete questionnaire(s) by themselves or with assistance * Provide informed written consent * Willing to consent for photography of radiation field * Available to return to Mayo Clinic in within 1 week post treatment for assessment (+/- 7 days). * At risk for developing ≥ grade 2 dermatitis radiation as determined by treating Radiation Oncology clinician * Biologic effective dose of \>42 Gy10 as calculated using the web site EQD2.com. Exclusion Criteria: * Unable to provide informed consent * Patients with active rash, pre-existing dermatitis, lupus or scleroderma within the treatment area that may make skin assessment for the study difficult * Known history of developing an allergic reaction after using a product containing cyanoacrylate or acrylates * Subject has a medical condition that in the opinion of the investigator should exclude him/her from participating in the study * Subject has been enrolled in an investigational study where product was applied to the proposed study site within 30 days of the screening visit * The skin area affected by radiation requires treatment with a concomitant medication or product (if applicable)
References
Publications (0)
Data not yet available
No reference posted for this study.